Development of the Ketamine Side Effect Tool (KSET)

Imagem de Miniatura
Arquivos
art_SHORT_Development_of_the_Ketamine_Side_Effect_Tool_KSET_2020.PDF.pdf (423.36 KB)
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
SHORT, Brooke
DONG, Vanessa
GALVEZ, Veronica
VULOVIC, Vedran
MARTIN, Donel
BAYES, Adam J.
ZARATE, Carlos A.
MURROUGH, James W.
MCLOUGHLIN, Declan M.
RIVA-POSSE, Patricio
Citação
JOURNAL OF AFFECTIVE DISORDERS, v.266, p.615-620, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Currently, no specific, systematic assessment tool for the monitoring and reporting of ketamine-related side effects exists. Our aim was to develop a comprehensive Ketamine Side Effect Tool (KSET) to capture acute and longer-term side effects associated with repeated ketamine treatments. Methods: Informed by systematic review data and clinical research, we drafted a list of the most commonly reported side effects. Face and content validation were obtained via feedback from collaborators with expertise in psychiatry and anaesthetics, clinical trial piloting and a modified Delphi Technique involving ten international experts. Results: The final version consisted of four forms that collect information at time points: screening, baseline, immediately after a single treatment, and longer-term follow-up. Instructions were developed to guide users and promote consistent utilisation. Limitations: Further evaluation of feasibility, construct validity and reliability is required, and is planned across multiple international sites. Conclusions: The structured Ketamine Side Effect Tool (KSET) was developed, with confirmation of content and face validity via a Delphi consensus process. This tool is timely, given the paucity of data regarding ketamine's safety, tolerability and abuse potential over the longer term, and its recent adoption internationally as a clinical treatment for depression. Although based on data from depression studies, the KSET has potential applicability for ketamine (or derivatives) used in other medical disorders, including chronic pain. We recommend its utilisation for both research and clinical scenarios, including data registries.
Palavras-chave
Ketamine, Side effects, Safety, Depression, Ketamine Side Effect Tool (KSET)
URI
https://observatorio.fm.usp.br/handle/OPI/36996
Referências
  1. Agency National Patient Safety, 2007, SAF DOS MED SAF INC
  2. Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726
  3. Bent S, 2006, ANN INTERN MED, V144, P257, DOI 10.7326/0003-4819-144-4-200602210-00007
  4. Benton A. L., 1989, MULTILINGUAL APHASIA
  5. Blier P, 2012, BIOL PSYCHIAT, V72, pE11, DOI 10.1016/j.biopsych.2012.02.039
  6. Conners C.K., 2000, MUTLIHEALTH SYSTEMS
  7. Dalkey N, 1963, MANAGE SCI, V9, P9
  8. Delis D. C., 2000, CALIFORNIA VERBAL LE
  9. Delis DC, 2001, DELIS KAPLAN EXECUTI
  10. Diamond PR, 2014, J PSYCHOPHARMACOL, V28, P536, DOI 10.1177/0269881114527361
  11. Eubank BH, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0165-8
  12. Galvez V, 2018, J PSYCHOPHARMACOL, V32, P397, DOI 10.1177/0269881118760660
  13. George D, 2017, AM J GERIAT PSYCHIAT, V25, P1199, DOI 10.1016/j.jagp.2017.06.007
  14. Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x
  15. Irwin SA, 2013, J PALLIAT MED, V16, P958, DOI 10.1089/jpm.2012.0617
  16. Jarernsiripornkul N, 2002, BRIT J CLIN PHARMACO, V53, P318, DOI 10.1046/j.0306-5251.2001.01547.x
  17. Jentsch JD, 1997, NEUROPSYCHOPHARMACOL, V17, P92, DOI 10.1016/S0893-133X(97)00034-1
  18. Kim J, 2019, NEW ENGL J MED, V381, P1, DOI 10.1056/NEJMp1903305
  19. KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0
  20. Mandillo S, 2003, BEHAV PHARMACOL, V14, P533, DOI 10.1097/00008877-200311000-00006
  21. Mathew SJ, 2012, CNS DRUGS, V26, P189, DOI 10.2165/11599770-000000000-00000
  22. McGirr A, 2015, PSYCHOL MED, V45, P693, DOI 10.1017/S0033291714001603
  23. Meshkat B., 2014, J HOSP ADM, V3, P8
  24. Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535
  25. Morgan CJA, 2010, ADDICTION, V105, P121, DOI 10.1111/j.1360-0443.2009.02761.x
  26. Morgan CJA, 2004, PSYCHOPHARMACOLOGY, V172, P298, DOI 10.1007/s00213-003-1656-y
  27. Morgan CJA, 2004, NEUROPSYCHOPHARMACOL, V29, P208, DOI 10.1038/sj.npp.1300342
  28. Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15
  29. Pope A, 2010, BRIT J PSYCHIAT, V197, P67, DOI 10.1192/bjp.bp.109.070961
  30. Rey A., 1964, EXAMEN CLIN PSYCHOL
  31. Schoevers RA, 2016, BRIT J PSYCHIAT, V208, P108, DOI 10.1192/bjp.bp.115.165498
  32. Sheftell FD, 2004, HEADACHE, V44, P978, DOI 10.1111/j.1526-4610.2004.04191.x
  33. Shiroma PR, 2014, INT J NEUROPSYCHOPH, V17, P1805, DOI 10.1017/S1461145714001011
  34. Short B, 2018, LANCET PSYCHIAT, V5, P65, DOI 10.1016/S2215-0366(17)30272-9
  35. Smith A., 1991, SYMBOL DIGIT MODALIT
  36. World Health Organization, 2015, KET INN UPD REV REP

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/21